A comparison between double and triple therapies of octreotide, galanin and serotonin on a rat colon carcinoma.
Sixty female nude mice (C578L/6jBom-nu) were injected with 100 microl cell suspension containing 2 x 10(6) viable cells of an N-methyl-N-nitroguanidine-induced rat colonic adenocarcinoma. After seven days the animals were divided into five groups. The first group received only saline and served as a control group. The second group received a triple therapy of octreotide, galanin and serotonin (20 microg/kg). The last three groups received double therapies of octreotide/galanin, octreotide/serotonin or galanin/serotonin (20 microg/kg). They were treated twice a day for five days. Tumour volume and weight, relative volume density of tumour-feeding blood vessels and of tumour necrotic tissue, as well as apoptotic and proliferation indices were determined. Animal weight, food consumption, faeces weight and its water content were recorded before and after treatment. Tumour volume was significantly reduced only in the group that received the triple therapy. The volume density of the tumour-feeding blood vessels was significantly reduced in the treated groups with the exception of the group that received octreotide and serotonin. Increased relative volume density of tumour necrotic tissue occurred only in the group treated with triple therapy. Apoptotic indices were significantly increased in all treated groups. No statistical difference was found between treated animals and controls regarding proliferation indices, food consumption, faeces weight and water content or animal weight. In conclusion, double therapy using two of the gastrointestinal bioactive substances, octreotide, galanin and serotonin, has certain effects on colon cancer cells. To cause a considerable tumour necrosis, triple therapy seems to be required. Both double and triple therapy seem to lack obvious side-effects.
Sitohy
B
B
Institute of Public Health and Clinical Medicine, Department of Medicine, Section for Gastroenterology and Hepatology, University Hospital, Umeå, Sweden.
El-Salhy
M
M
D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D002277:Carcinoma / Q000188:drug therapy*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004347:Drug Interactions / Q000502:physiology; D016166:Free Radical Scavengers; D019004:Galanin / Q000494:pharmacology*; D051379:Mice; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000503:physiopathology; D015282:Octreotide / Q000494:pharmacology*; D051381:Rats; D012701:Serotonin / Q000494:pharmacology*
D018931:Antineoplastic Agents, Hormonal; D016166:Free Radical Scavengers; D012701:Serotonin; D019004:Galanin; D015282:Octreotide